Clinical efficacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients (pts) with chemotherapy-refractory metastatic urothelial carcinoma (mUC) either naïve (n) or refractory (r) to checkpoint inhibitor (CPI).
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Rosa Nadal, Amir Mortazavi, Mark N. Stein, Sumanta K. Pal, Daniel K Lee, Howard L. Parnes, Yang-Min Ning, Lisa M. Cordes, Mohammadhadi H. Bagheri, Ryan Thompson, Christian Mayfield, Seth M. Steinberg, Paul Monk, Primo Lara, Rene Costello, Piyush K. Agarwal, Donald Bottaro, William L. Dahut, Andrea B. Apolo
Institutions: National Institutes of Health, National Cancer Institute, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Wexner Medical Center, Columbia University Irving Medical Center, City Of Hope National Medical Center, United States Food and Drug Administration, National Institutes of Health Clinical Center, The Ohio State University, University of California, Davis, Center for Cancer Research
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2890827908